Jpmorgan Chase & CO Pharma Cyte Biotech, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19 shares of PMCB stock, worth $33. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 18
5.56%
Holding current value
$33
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PMCB
# of Institutions
31Shares Held
1.12MCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6328KShares$579,6800.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$340,5240.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$312,5900.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$162,9937.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$146,4260.18% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $36.7M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...